Utilization of Type 2 Diabetes Mellitus Products in the Sentinel Distributed Database, 2008-2024

Post-market safety studies of type 2 diabetes (T2D) products are routinely conducted using the FDA's Sentinel Distributed Database (SDD) of commercial and public insurance claims. Contemporary information on patterns of T2D product use in the SDD can inform the feasibility of complex exposure modeling for safety analyses. This poster summarizes a study that characterized over 9.4 million initiators of four T2D drug classes in the FDA Sentinel System from 2008 through 2024. It was presented at the 2025 ISPE Annual Meeting.